MAZE
Maze Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.52
−3.92%Aug 17, 2026, 00:00 UTC
Maze Therapeutics, Inc. appointed Paula A. Johnson and Sophie Kornowski as Class III and Class I directors, respectively, effective August 13, 2026, each receiving an option to purchase 36,000 shares of the company's common stock.